Humanized bronchial organ and construction method thereof
By using HBE135-E6E7 cells in three-dimensional matrix gel and adjusting the medium conditions, human bronchial organoids were constructed, which solved the problem of cell source and scale, and achieved efficient and standardized organoid culture, reducing costs and time, and suitable for Simulate the real internal environment for experiments.
Patent Information
- Application Number
- CN202411196161.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-26
AI Technical Summary
In organoid culture technology, there are problems such as difficulty in cell source, difficulty in achieving scale and standardization, and high cost and time, especially in the culture of human bronchial organoids.
By using HBE135-E6E7 cells in three-dimensional matrix gel, the composition and conditions of the culture medium are changed, cell induction and differentiation are carried out, human bronchial organoids are constructed, and the formation of cell spheres is promoted using two-stage culture medium (proliferation and differentiation medium) is used to promote the formation of cell spheres. and differentiation.
It is realized that human bronchial organoids are cultivated in three-dimensional structures, and the airway epithelial markers are well expressed, which simplifies the batch culture process, reduces cost and time, and improves the repeatability and standardization of the experiment.
Smart Images

Figure CN119020261A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of organoid culture, and in particular to a human bronchial organoid and a construction method thereof. Background Art
[0002] In the past decade, organoid research has entered a golden age, marking a key shift in the biomedical field. Organoids make up for the shortcomings of simple cell models and complex animal models in traditional research, providing an important experimental basis for the study of key functions of living organisms, and have great theoretical significance and application prospects in disease mechanism research, drug screening, regenerative medicine, and biomaterial evaluation.
[0003] Currently, non-tumor organoids are mainly derived from pluripotent stem cells and adult stem cells, and the principle is based on the potential of stem cells to differentiate and self-renew. Among them, adult stem cells refer to undifferentiated cells that exist in a differentiated tissue, and organoids derived from adult epithelial stem cells are the most mature and widespread. Adult stem cells in the human respiratory system mainly include primary human bronchial epithelial cells, primary human type II alveolar epithelial cells, primary human nasal mucosal epithelial cells, etc. At present, the organoids cultured from the above primary cells have been reported in the literature.
[0004] However, organoid culture is a complex technology with multiple challenges and difficulties. The first is the issue of cell sources. Obtaining suitable stem cells or progenitor cells may be ethical and technically difficult, and the efficiency of inducing pluripotent stem cells to differentiate into specific organ cells is not high. Secondly, the scale and standardization of organoids is another major challenge. Large-scale and consistent organoid production is difficult to achieve, and the reproducibility between different batches and laboratories is poor, lacking a unified quality control standard. Finally, there is the cost and time issue of organoids. The organoid culture process is time-consuming, usually taking weeks to months, and the cost of materials such as culture medium and various growth factors is high.
[0005] The HBE135-E6E7 cell line was established from the normal bronchial epithelium of a 54-year-old man who underwent lobectomy for squamous cell carcinoma. It was immortalized after infection with the recombinant retrovirus LXSN16E6E7 containing the human papillomavirus (HPV) E6E7 gene. However, since serum is not involved in the culture medium, freezing reagents, and passaging process, it is speculated that the cells still have a certain degree of stemness. The number of cell lines that can be passaged, the time and difficulty of culture are lower than those of primary cells. If airway organoids can be cultured using this cell line, the above problems will be greatly improved. However, there are no reports on the use of human bronchial epithelial cell lines with a certain degree of stemness for bronchial organoid culture. Summary of the invention
[0006] The purpose of the present invention is to provide a human bronchial organoid and a construction method thereof to solve the problems existing in the above-mentioned prior art.
[0007] To achieve the above object, the present invention provides the following solutions:
[0008] One of the technical solutions of the present invention is a method for constructing a human bronchial organoid, comprising the following steps:
[0009] (1) Human bronchial epithelial cells were cultured in human bronchial epithelial cell complete medium, and when the cell density grew to 90%, they were passaged at a ratio of 1:2;
[0010] (2) culturing subcultured human bronchial epithelial cells in airway organoid proliferation medium to obtain intermediate cell spheres;
[0011] (3) Cultivating the intermediate cell spheres in an airway organoid differentiation medium to obtain the human bronchial organoids.
[0012] The second technical solution of the present invention is the human bronchial organoids constructed by the construction method.
[0013] Based on the above technical solution, the present invention has the following technical effects:
[0014] The culture method provided by the present invention can always culture HBE135-E6E7 cells into bronchial organoids in three-dimensional matrix gel. It only needs to simply change the composition of the culture medium and adjust the culture conditions to induce the cells into intermediate cell clusters and then differentiate into bronchial organoids. The organoids have a better three-dimensional structure than cells, and well express a variety of markers in the airway epithelium, which helps to simulate the real in vivo environment. Immunofluorescence identification found that the organoids well expressed various markers of airway tissue, which is helpful for standardized batch culture, and the bronchial organoids are used to simulate the in vivo environment for various tests. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0016] Figure 1 This is a light microscopic picture of HBE135-E6E7 cells initially seeded into matrix gel in Example 1.
[0017] Figure 2This is a light microscopic picture of the HBE135-E6E7 cells in Example 1 forming intermediate cell spheres 7 days after being seeded in matrix gel.
[0018] Figure 3 This is a light microscopic photograph of the intermediate cell sphere in Example 1 after 7 days of differentiation.
[0019] Figure 4 This is a light microscopic photograph of the intermediate cell sphere in Example 1 that formed an organoid after differentiation for 14 days.
[0020] Figure 5 This is a picture of the immunofluorescence identification of the airway basal cell marker Kertin5 in organoids in Example 2.
[0021] Figure 6 This is a picture of the immunofluorescence identification of the airway ciliary cell marker Acetyl-α-Tubulin in organoids in Example 2.
[0022] Figure 7 This is a picture of immunofluorescence identification of the airway Clara cell marker CC10 in organoids in Example 2. DETAILED DESCRIPTION
[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0024] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0025] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0026] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.
[0027] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0028] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or have been disclosed.
[0029] An embodiment of the present invention provides a method for constructing a human bronchial organoid, comprising the following steps:
[0030] (1) Human bronchial epithelial cells were cultured in human bronchial epithelial cell complete medium, and when the cell density grew to 90%, they were passaged at a ratio of 1:2;
[0031] (2) culturing subcultured human bronchial epithelial cells in airway organoid proliferation medium to obtain intermediate cell spheres;
[0032] (3) Cultivating the intermediate cell spheres in an airway organoid differentiation medium to obtain the human bronchial organoids.
[0033] In some specific embodiments, the human bronchial epithelial cells include HBE135-E6E7 cells.
[0034] In some specific embodiments, the preparation method of the human bronchial epithelial cell complete culture medium is: add 0.005 mg / mL insulin to the keratinocyte complete culture medium containing 5 ng / ml human recombinant epidermal growth factor, 0.05 mg / mL bovine pituitary extract and 500 ng / mL hydrocortisone, and mix well.
[0035] In some specific embodiments, the preparation method of the airway organoid proliferation medium is: add 10 mL of airway organoid inoculation supplement to 90 mL of airway organoid basal medium and mix thoroughly; add 1 mL of penicillin-streptomycin dual antibody before use.
[0036] In some specific embodiments, the culturing time in the airway organoid proliferation medium is 7 to 9 days.
[0037] In some specific embodiments, in step (2), HBE135-E6E7 cells are resuspended in 60% Matrigel + 40% airway organoid proliferation medium, placed in a 37°C incubator for 30 minutes, and after the Matrigel solidifies, the airway organoid proliferation medium is added around the Matrigel for culture, and the airway organoid proliferation medium is replaced every 3 days. The fresh medium is preheated to 37°C before each replacement.
[0038] In some specific embodiments, the preparation method of the airway organoid differentiation medium is: add 40 mL of airway organoid differentiation supplement to 360 mL of airway organoid basal medium and mix thoroughly; add 800 μL of heparin solution, 2 mL of hydrocortisone solution and 4 mL of penicillin-streptomycin dual antibody.
[0039] In some specific embodiments, the culturing time in the airway organoid differentiation medium is 14 to 16 days.
[0040] In some specific embodiments, in step (3), after the HBE135-E6E7 cells grow into cell spheres, the airway organoid proliferation medium surrounding the matrix gel is replaced with an airway organoid differentiation medium, which is replaced every 3 days. The fresh medium is preheated to 37° C. before each replacement.
[0041] The embodiments of the present invention also provide human bronchial organoids constructed by the construction method.
[0042] The present invention performs serum-free cell culture on human bronchial epithelial cells 135-E6E7 (HBE135-E6E7). After the growth is stable, the cells are converted from 2D adherent culture to 3D culture. At the same time, the bronchial cell culture medium is replaced with an airway organoid proliferation medium. After the cells grow into a cell ball of a certain volume, the culture medium is replaced with an airway organoid differentiation medium. After 2 weeks, branched bronchial organoids can be cultured. Immunofluorescence identification found that the organoids well expressed various markers of airway tissue, which is helpful for standardized batch culture. The bronchial organoids are used to simulate the in vivo environment for various tests. The operation is simple, easy to popularize, and does not require special instruments. Conventional cell culture laboratories can operate.
[0043] HBE135-E6E7 cells were cultured in a serum-free bronchial epithelial cell-specific culture medium and were passaged every 4 days. Multiple passages were performed to retain cell seeds for subsequent organoid culture. Airway organoid proliferation medium was used to convert the above cells from 2D to 3D culture, and intermediate cell spheres were obtained after 7 days. Airway organoid differentiation medium was used to differentiate the above intermediate cell spheres, and branched bronchial organoids were obtained after 14 days.
[0044] The HBE135-E6E7 cells used in the present invention are immortalized cell lines, but because they do not involve serum during the culture process, they may retain a certain degree of stemness and have the potential for directional growth and differentiation. Cell lines are easy to obtain and sufficient in quantity relative to primary cells, and can be cultured in large quantities into human bronchial organoids. To avoid differentiation of HBE135-E6E7 cells, a serum-free bronchial epithelial cell-specific culture medium is used during the culture process, Accutase cell digestion solution is used during the digestion process of subculture, and PBS dilution is used to terminate the digestion, and serum-free cell freezing solution is used during freezing.
[0045] The embodiment of the present invention also provides a method for immunofluorescence identification of the above-mentioned bronchial organoids, comprising the steps of:
[0046] (1) Fixing, dehydrating, embedding, and slicing the bronchial organoids wrapped in matrix gel as a whole;
[0047] The fixative included 2% paraformaldehyde (PFA) and 0.1% glutaraldehyde, and the fixation condition was room temperature for 1 hour; 15% sucrose solution was used for dehydration at 4°C overnight, and dehydration was completed when the organoids precipitated to the bottom of the tube; OCT was used as the embedding agent; the slice thickness was 5 μm.
[0048] (2) Frozen sections were subjected to antigen retrieval, endogenous peroxidase blocking, permeabilization, and blocking treatments;
[0049] In order to avoid the cross-linking of proteins by methylene bridges generated by PFA during the fixation process, which shields the effects of antigenic sites, antigen repair is performed on the sections. Since organoids are easier to detach than tissues, the required antigen repair temperature is lower and the time is shorter. The application conditions here are high heat in a microwave oven until boiling once, low heat for 5 minutes, and multiple boilings should not be performed. Use 1× sodium citrate buffer as an antigen repair agent, heat it on high heat in a microwave oven until boiling once, then cook on low heat for 5 minutes; endogenous peroxidase blocking conditions are 3% H2O2 at room temperature for 10 minutes; permeabilization conditions are 0.1% Triton X-100 at room temperature for 10 minutes; blocking conditions are 5% BSA at room temperature for 1 hour.
[0050] (3) Frozen sections were incubated with primary antibody, secondary antibody, and DAPI in sequence until sealing.
[0051] The incubation conditions for primary antibody, secondary antibody and DAPI were 4°C overnight, room temperature for 1 hour, and room temperature for 20 minutes, respectively; the slides were sealed with a sealing medium containing DAPI anti-fluorescence quenching.
[0052] The culture method provided by the present invention can culture bronchial organoids completely in a 3D matrix gel environment. The culture method uses a finished airway organoid culture medium, uses less exogenous induction reagents, and uses a two-stage (proliferation-differentiation) nutritional environment adjustment according to the airway organoid culture medium instructions to promote the differentiation of cell spheres into branched bronchial organoids.
[0053] The main materials and sources used in the examples are as follows:
[0054] HBE135-E6E7 human cell line: Zhongqiao Xinzhou Company, catalog number: ZQ0001 (introduced from ATCC, catalog number CRL-2741).
[0055] Keratinocyte complete culture medium: Shanghai Yuanpei Biotechnology Co., Ltd., product number C120JV.
[0056] Recombinant human insulin: Yisheng Biotechnology Co., Ltd., product number 40112ES25.
[0057] Accutase cell digestion solution: Zhongqiao Xinzhou Company, product number CSP140.
[0058] 100 mm cell culture dish: China Zhenxuan Co., Ltd., catalog number 12310.
[0059] D-PBS buffer: Sevier Company, product number G4200-500ML.
[0060] PneumaCult TM Airway Organoid Kit: Stemcell, Canada, catalog number 05060. Contains components (1) PneumaCult TM Airway Organoid Basal Medium, Catalog No. 05061; (2) PneumaCult TM Airway Organoid Seeding Supplement, Catalog No. 05062; (3) PneumaCult TM Airway Organoid Differentiation Supplement, Catalog No. 05063.
[0061] Heparin solution: Stemcell, Canada, catalog number 07980.
[0062] Hydrocortisone: Stemcell, Canada, product number 07925.
[0063] Basement membrane matrix gel: Corning, USA, product number 354234.
[0064] Penicillin-streptomycin dual antibody: Thermo Fisher Scientific, catalog number: 15140122.
[0065] 24-well flat-bottom multiwell cell culture plate treated with tissue culture: Corning, USA, product number 353226.
[0066] OCT embedding medium: Sakura Co., Ltd., Japan, product number 4583.
[0067] Sodium citrate buffer (50×): Beijing Solebow Technology Co., Ltd., catalog number C1013.
[0068] Triton X-100: Shanghai Biotime Biotechnology Co., Ltd., catalog number P0096-100ml.
[0069] Bovine serum albumin (BSA) powder: Beijing Solebow Technology Co., Ltd., catalog number A8010.
[0070] CC10 antibody: Wuhan Tri-Eagle Biotechnology Co., Ltd., catalog number 10490-1-AP.
[0071] Acetylated α-Tublin antibody: Cell Signaling Technology, USA, catalog number 5335T.
[0072] Keratin 5 antibody: Cell Signaling Technology, USA, catalog number 71536.
[0073] Goat anti-rabbit IgG H&L (Alexa 555): Abcam, UK, catalog number ab150078.
[0074] DAPI stock solution: Sigma, Germany, catalog number MBD0015.
[0075] Adhesive slides: Jiangsu Shitai Experimental Equipment Co., Ltd., item number 188105W.
[0076] Cover glass: Jiangsu Shitai Experimental Equipment Co., Ltd., catalog number 803402810.
[0077] Light microscopy images were taken using a Leica optical microscope and imaging system.
[0078] Fluorescence images were taken using a Zeiss LSM880 confocal laser microscope equipped with an Airyscan unit.
[0079] Frozen sections were cut using a Leica CM1950 cryostat.
[0080] The main culture medium used in the embodiments of the present invention is:
[0081] (1) Preparation of complete culture medium for human bronchial epithelial cells: Add 0.005 mg / mL insulin to complete culture medium for keratinocytes containing 5 ng / mL human recombinant epidermal growth factor (EGF), 0.05 mg / mL bovine pituitary extract, and 500 ng / mL hydrocortisone, and mix well;
[0082] (2) Preparation of airway organoid proliferation medium: thaw the airway organoid seeding supplement at room temperature and shake well; add 10 mL of airway organoid seeding supplement to 90 mL of airway organoid basal medium and mix thoroughly; add 1 mL of penicillin-streptomycin before use;
[0083] (3) Preparation of airway organoid differentiation medium: thaw airway organoid differentiation supplement at room temperature and shake well; add 40 mL of airway organoid differentiation supplement to 360 mL of airway organoid basal medium and mix thoroughly; add 800 μL of heparin solution, 2 mL of hydrocortisone solution and 4 mL of penicillin-streptomycin dual antibody.
[0084] Example 1
[0085] HBE-135 cell-derived organoid culture.
[0086] The specific steps include:
[0087] 1-1) The culture flask containing HBE135-E6E7 cells purchased by the company was disinfected by wiping with alcohol and then placed in a 37°C cell culture incubator for 4 hours, and then the culture medium was replaced with complete human bronchial epithelial cell culture medium.
[0088] 1-2) When the cell density grows to 90%, the cells are subcultured in a 100 mm cell culture dish at a ratio of 1:2, and the culture medium is replaced every two days. The cells are cryopreserved repeatedly.
[0089] 1-3) One day in advance, preheat the 24-well plate in a 37°C cell culture incubator and thaw the matrix gel on ice; 2 hours in advance, restore the airway organoid proliferation medium, D-PBS buffer and Accutase cell digestion solution to room temperature and precool the 1 mL and 200 μL sterile pipette tip boxes on ice.
[0090] 1-4) Aspirate the original culture medium from the HBE culture dish, add 5 mL of D-PBS buffer to wash the cells and then aspirate.
[0091] 1-5) Add 2.5 mL of Accutase cell digestion solution to the culture dish and incubate at 37°C for 5-7 minutes until the cells fall off by gently tapping the bottom of the dish. Add 4.5 mL of D-PBS buffer to terminate the digestion and transfer to a 15 mL centrifuge tube.
[0092] 1-6) Centrifuge the cell suspension at 400×g for 5 min and discard the supernatant.
[0093] 1-7) Resuspend the cell pellet in an ice-cold mixture of 60% Matrigel and 40% Airway Organoid Proliferation Medium, avoiding the formation of bubbles.
[0094] 1-8) Quickly add 50 μL of ice-cold mixture mixed with HBE cells to the center of each well of a 24-well cell culture plate. The final concentration should be 2×10 3 cells / 50μL.
[0095] 1-9) Incubate the 24-well plate in a 37°C incubator for 30 min to allow the matrix gel to solidify.
[0096] 1-10) After the matrix gel solidifies, add 500 μL of airway organoid proliferation medium to each well and culture the cells in an incubator at 37°C and 5% CO2. The airway organoid proliferation medium should be changed every 3 to 4 days, making sure to pre-warm the fresh medium before changing the medium.
[0097] 1-11) After 7 days of culture in airway organoid proliferation medium, intermediate cell spheres were formed. Figure 2 As shown, it presents a round solid structure, indicating that the cells are transformed from 2D to 3D culture. The intermediate cell spheres obtained after 3D culture can also be passaged and grown again as intermediate cell spheres in matrix gel, and can still be differentiated into bronchial organoids later, indicating that the conversion of culture methods does not affect the proliferation potential of the cell spheres.
[0098] 1-12) Remove the airway organoid proliferation medium and replace it with airway organoid differentiation medium. The airway organoid differentiation medium should be changed every 3 to 4 days. Make sure to preheat the fresh medium before changing the medium. After 7 days of culture, the round solid cell spheres will become irregular solid organoids. Figure 3 As shown; after 7 days of culture, it becomes a branched organoid, as shown Figure 4 shown.
[0099] Example 2
[0100] Immunofluorescence characterization of bronchial organoids
[0101] In order to understand whether the composition of the formed organoids is consistent with the airway tissue, the present invention then subjected the bronchial organoids cultured in Example 1 to frozen section processing, and then used immunofluorescence technology to mark different airway markers (such as basal cell marker - Kertin5, ciliated cell marker - Acetyl-α-Tubulin, Clara cell marker - CC10, etc.).
[0102] The specific steps include:
[0103] 2-1) Rinse each well with 1 mL of PBS solution without damaging the matrix gel.
[0104] 2-2) Add 500 μL of a mixed fixative solution of 2% PFA + 0.1% glutaraldehyde to each well and fix at room temperature for 1 hour. Then wash with PBS for 5 minutes × 3 times. After washing, aspirate the PBS and be careful not to damage the matrix gel.
[0105] 2-3) Use a small cell scraper to carefully scoop the matrix gel containing the organoids into a 15 mL centrifuge tube containing 15% sucrose solution and place it in a 4°C refrigerator overnight. When the organoids sink to the bottom of the tube, dehydration is complete.
[0106] 2-4) Centrifuge at 1500 rpm for 5 min and carefully discard the upper sucrose solution.
[0107] 2-5) Cut off the tip of the 1mL pipette and rinse the pipette with 1% BSA to prevent the organoids from sticking to the pipette. Suck the organoids into the center of the mold filled with OCT, being careful not to create bubbles, and then quickly transfer to dry ice for quick freezing.
[0108] 2-6) The mass was cut into 5 μm sections using a Leica cryostat and the sections were stored in a -80°C freezer.
[0109] 2-7) The slices were returned to room temperature before use and washed once with PBS to remove OCT.
[0110] 2-8) Place the slices in 1× sodium citrate buffer, heat in a microwave oven on high heat until boiling, then cook on low heat for 5 minutes; wait for the repair solution to cool to room temperature, and wash with PBS for 5 minutes × 3 times.
[0111] 2-9) The organoids on the slices were circled with an immunohistochemistry pen, and 3% H2O2 was added into the circle to block endogenous peroxidase. After 10 min at room temperature, the slices were washed with PBS for 5 min × 3 times.
[0112] 2-10) 0.1% Triton X-100 was added dropwise to the circle for permeabilization. After 15 min at room temperature, the circle was washed with PBS for 5 min × 3 times.
[0113] 2-11) Add 5% BSA into the circle and block at room temperature for 1 hour.
[0114] 2-12) The above-mentioned airway tissue markers (Kertin5, Acetyl-α-Tubulin, CC10) antibodies were prepared with 5% BSA solution at a ratio of 1:200 to prepare primary antibody reagents. The primary antibody reagents were dripped into the circle, incubated overnight at 4°C, and then washed with PBS for 5 min × 3 times.
[0115] 2-13) Goat anti-rabbit fluorescent antibody was prepared with 5% BSA solution at a ratio of 1:1000 to prepare secondary antibody reagent. The secondary antibody reagent was dropped into the circle, incubated at room temperature for 1 hour, and then washed with PBS for 5 minutes × 3 times.
[0116] 2-14) DAPI stock solution was prepared with 5% BSA solution at a ratio of 1:1000 to form DAPI working solution. DAPI working solution was dropped into the circle, incubated at room temperature for 20 minutes, and then washed with PBS for 5 minutes × 3 times.
[0117] 2-15) Drop the DAPI anti-fluorescence quenching mounting medium on the organoid slices, place the coverslip in contact with the organoid first and then slowly cover it, trying to avoid bubbles.
[0118] Immunofluorescence results Figures 5 to 7 As shown, the airway organoids well expressed the basal cell marker Kertin5, the ciliated cell marker Acetyl-α-Tubulin, and the Clara cell marker CC10, and the composition was similar to that of airway tissue.
[0119] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A method for constructing human bronchial organoids. It is characterized in that The following steps are involved: (1) Human bronchial epithelial cells were cultured in human bronchial epithelial cell complete medium, and when the cell density grew to 90%, they were passaged at a ratio of 1:2; (2) culturing subcultured human bronchial epithelial cells in airway organoid proliferation medium to obtain intermediate cell spheres; (3) Cultivating the intermediate cell spheres in an airway organoid differentiation medium to obtain the human bronchial organoids.
2. The construction method according to claim 1, It is characterized in that The human bronchial epithelial cells include HBE135-E6E7 cells.
3. The construction method according to claim 1, It is characterized in that The preparation method of the human bronchial epithelial cell complete culture medium is as follows: 0.005 mg / mL insulin is added to a keratinocyte complete culture medium containing 5 ng / ml human recombinant epidermal growth factor, 0.05 mg / mL bovine pituitary extract and 500 ng / mL hydrocortisone, and the mixture is mixed.
4. The construction method according to claim 1, It is characterized in that The preparation method of the airway organoid proliferation medium is as follows: 10 mL of airway organoid inoculation supplement is added to 90 mL of airway organoid basal medium and mixed thoroughly; and 1 mL of penicillin-streptomycin dual antibody is added before use.
5. The construction method according to claim 1, It is characterized in that The culture time in the airway organoid proliferation medium is 7 to 9 days.
6. The construction method according to claim 1, It is characterized in that The airway organoid differentiation medium is prepared by adding 40 mL of airway organoid differentiation supplement to 360 mL of airway organoid basal medium and mixing thoroughly; Add 800 μL of heparin solution, 2 mL of hydrocortisone solution and 4 mL of penicillin-streptomycin dual antibody.
7. The construction method according to claim 1, It is characterized in that The culture time in the airway organoid differentiation medium is 14 to 16 days.
8. Human bronchial organoids constructed by the construction method according to any one of claims 1 to 7.
Citation Information
Cited By
Differentiation culture method for differentiating bronchial epithelial stem / progenitor cells into bronchial epithelial organoid
CN120082501A
Differentiation culture methods for bronchial epithelial stem / progenitor cells to differentiate into bronchial epithelial organoids
CN120082501B
Method for visually tracking mycoplasma pneumoniae infected human bronchial organoid
CN122303134A
